Hormone Replacement Therapy after Cervical Cancer with Jason Wright
In this episode of the IJGC podcast, Editor-in-Ch…
BMJ talk medicine · BMJ Group
January 16, 202325m 18s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Jason Wright to discuss hormone replacement therapy after cervical cancer. Dr. Wright is the Sol Goldman Associate Professor and Chief of the Division of Gynecologic Oncology at Columbia University.
Highlights:
- Among cervical cancer patients <50 years of age who underwent surgery including oophorectomy or primary radiation, only 39% received estrogen replacement therapy.
- In patients who did receive estrogen replacement therapy the duration of use was short, with a median of only 60 days.
- Black patients were significantly less likely to receive estrogen replacement therapy than White patients.